Metabolic functional imaging for tumor radio sensitivity monitoring

被引:11
作者
Belkacemi, Yazid
Tsoutsou, Pelagia
Magne, Nicolas
Castadot, Pierre
Azria, David
机构
[1] Oscar Lambret Anti Canc Ctr, Dept Radiat Oncol, F-59020 Lille, France
[2] Univ Lille 2, Lille, France
[3] Metaxas Ctr, Dept Radiat Oncol, Piraeus, Greece
[4] Jules Bordet Anti Canc Inst, Dept Radiooncol, Brussels, Belgium
[5] Val Aurelle Anti Canc Ctr, Dept Radiat Oncol, Montpellier, France
[6] Inserm EMI0227, Montpellier, France
关键词
radiosensitivity; PET; radiation therapy; tumor response; nuclear imaging;
D O I
10.1016/j.critrevonc.2006.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Assessing tumor radiosensitivity before and during radiation therapy can be a crucial element in decision-making with regard to treatment. However, no known non-invasive test is available at present, which allows for a reliable evaluation of the radiosensitivity of a tissue subjected to radiotherapy. Among tests being evaluated, positron emission tomography (PET) is considered to be a promising method. The purpose of this review is to identify the tests and research paths that have recently been explored for the evaluation of tumor response to treatment after isotopic labeling revealed by nuclear imaging. The majority of the explored methodologies are based on the indirect evaluation of the radiosensitivity by cell proliferation or apoptosis, tissue oxygenation or hypoxia, intrinsic radiosensitivity of clonogenic cells, tumor metabolism and angiogenesis. The development of such methods would permit the adoption of a therapeutic regimen with respect to a given radiosensitivity of a tissue. Therefore, a given therapeutic strategy could be readjusted (by associating, for instance, a radiosensitizer of hypoxic cells) or even modified if it proved to be inadequate or when it presents an unfavorable cost-effectiveness ratio.
引用
收藏
页码:227 / 239
页数:13
相关论文
共 111 条
[1]  
Abe T, 2001, ANTICANCER RES, V21, P2115
[2]  
ADIEDJ A, 2001, DRUGS FUTURE, V26, P1087
[3]   Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy [J].
Allal, AS ;
Dulguerov, P ;
Allaoua, M ;
Haenggeli, CA ;
El Ghazi, EA ;
Lehmann, W ;
Slosman, DO .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1398-1404
[4]   Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate [J].
Anderson, HL ;
Yap, JT ;
Miller, MP ;
Robbins, A ;
Jones, T ;
Price, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2823-2830
[5]  
Antoch G, 2004, J NUCL MED, V45, P357
[6]   Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].
Bander, NH ;
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601
[7]   Towards prediction and modulation of treatment response [J].
Bartelink, H ;
Begg, A ;
Martin, JC ;
van Dijk, M ;
van't Veer, L ;
van der Vaart, P ;
Verheij, M .
RADIOTHERAPY AND ONCOLOGY, 1999, 50 (01) :1-11
[8]   In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography [J].
Barthel, H ;
Wilson, H ;
Collingridge, DR ;
Brown, G ;
Osman, S ;
Luthra, SK ;
Brady, F ;
Workman, P ;
Price, PM ;
Aboagye, EO .
BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2232-2242
[9]   Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results [J].
Baumann, M ;
Krause, M .
RADIOTHERAPY AND ONCOLOGY, 2004, 72 (03) :257-266
[10]   Mirror, mirror on the wall - Which is the greatest predictive assay of them all? [J].
Beitler, JJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05) :1272-1273